Nurix Therapeutics, Inc. — Form 10-Q

On April 6, 2026, Nurix and Sanofi (Genzyme Corporation) executed a Seventh Amendment to their long-standing Collaboration and License Agreement (originally dated December 19, 2019). The amendment permits Sanofi to continue research on STAT6 and an unnamed additional collaboration target after their respective research term expirations, during the applicable collaboration license periods. The amendment redefines several key terms including Licensed Product, Nurix Know-How, Nurix Patent, and introduces new definitions for Research Plan Completion Licensed Compounds. Critically, it modifies research results ownership: upon termination by Sanofi or Nurix under specified conditions, research results revert to Nurix after the Target Exclusivity Period expires, except for data concerning Sanofi Target Binders or Sanofi Materials. The amendment also clarifies Nurix's reversion rights to terminated licensed products and royalty obligations. Most financial terms and milestones remain redacted [*], preventing disclosure of dollar amounts and specific payment schedules.